About iBio

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals.

iBio has demonstrated the feasibility of developing and producing a wide range of products that are available for license along with the technology to bring them to patients.


About iBio Management Team

Investor Information

Investor Overview


High Resolution Logo - JPG Format